Anixa Biosciences (ANIX) Stock Price, News & Analysis

Company Overview

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom. ADAPT is designed to generate biomarker signatures for early detection and monitoring of cancer and other diseases, with initial studies focusing on breast and ovarian malignancies. This platform seeks to deliver non-invasive, blood-based tests that can aid in disease stratification and treatment decisions.

Since its founding, Anixa has engaged with academic institutions, government agencies and strategic partners to support its preclinical and clinical programs. The firm has leveraged grants and collaborations to advance its SARS-CoV-2 vaccine into regulatory review and to expand its oncology candidates into Phase II development. Headquartered in San Jose, California, Anixa maintains operations across the United States and continues to establish partnerships to extend its global research footprint.

Under the leadership of a management team with extensive experience in biotechnology, oncology and vaccine development, Anixa Biosciences is focused on translating its innovative platforms into clinically meaningful products. The company’s multidisciplinary approach, encompassing both therapeutic and diagnostic divisions, aims to address unmet needs in cancer and infectious disease through precision immunology solutions.

Key Stats

• Today's Range: $2.85 to $3.09
• 50-Day Range: $2.50 to $3.14
• 52-Week Range: $2.44 to $5.46
• Volume: 100,814 shs
• Average Volume: 148,454 shs
• Market Capitalization: $102.60 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.50
• Consensus Rating: Hold

Anixa Biosciences Stock Analysis - MarketRank™

Anixa Biosciences scored higher than 49% of companies evaluated by MarketBeat, and ranked 496th out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Hold

Consensus Rating

Anixa Biosciences has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Anixa Biosciences has a consensus price target of $8.50, representing about 177.8% upside from its current price of $3.06.

Amount of Analyst Coverage

Anixa Biosciences has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Anixa Biosciences is -9.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Anixa Biosciences is -9.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Anixa Biosciences has a P/B Ratio of 7.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.23% of the float of Anixa Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Anixa Biosciences has a short interest ratio ("days to cover") of 9.67.

Change versus previous month

Short interest in Anixa Biosciences has recently decreased by 9.28%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Anixa Biosciences does not currently pay a dividend.

Dividend Growth

Anixa Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.34

News Sentiment

Anixa Biosciences has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Anixa Biosciences this week, compared to 3 articles on an average week.

Search Interest

11 people have searched for ANIX on MarketBeat in the last 30 days. This is an increase of 83% compared to the previous 30 days.

MarketBeat Follows

3 people have added Anixa Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 1.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Anixa Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

26.40% of the stock of Anixa Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

29.13% of the stock of Anixa Biosciences is held by institutions.

ANIX Stock Analysis - Frequently Asked Questions

How have ANIX shares performed this year?

Anixa Biosciences' stock was trading at $3.12 on January 1st, 2026. Since then, ANIX stock has decreased by 1.9% and is now trading at $3.06.

How were Anixa Biosciences' earnings last quarter?

Anixa Biosciences Inc (NASDAQ:ANIX) issued its quarterly earnings data on Monday, March, 9th. The company reported ($0.08) earnings per share for the quarter, topping analysts' consensus estimates of ($0.09) by $0.01.

Who are Anixa Biosciences' major shareholders?

Anixa Biosciences' top institutional shareholders include Kestra Advisory Services LLC (0.15%) and Bank of New York Mellon Corp (0.14%). Insiders that own company stock include Lewis H Titterton Jr, Amit Kumar, Arnold M Baskies and Michael Catelani.
View institutional ownership trends.

How do I buy shares of Anixa Biosciences?

Shares of ANIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Anixa Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Anixa Biosciences investors own include Invesco QQQ (QQQ), SPDR Dow Jones Industrial Average ETF Trust (DIA), SPDR S&P 500 ETF Trust (SPY), Coty (COTY), AbbVie (ABBV), Adverum Biotechnologies (ADVM) and Avino Silver & Gold Mines (ASM).

Company Calendar

• Last Earnings: 3/09/2026
• Today: 5/06/2026
• Next Earnings (Estimated): 5/27/2026
• Fiscal Year End: 10/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ANIX
• CIK: 715446
• Web: www.anixa.com
• Phone: (408) 708-9808
• Fax: 631-549-5974
• Employees: 5
• Year Founded: 1982

Price Target and Rating

• Average Price Target for Anixa Biosciences: $8.50
• High Price Target: $10.00
• Low Price Target: $7.00
• Potential Upside/Downside: +177.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.33)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$10.93 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -70.95%
• Return on Assets: -62.53%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 12.18
• Quick Ratio: 12.18

Sales & Book Value

• Annual Sales: $210 thousand
• Price / Sales: 488.58
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.42 per share
• Price / Book: 7.29

Miscellaneous

• Outstanding Shares: 33,530,000
• Free Float: 24,677,000
• Market Cap: $102.60 million
• Optionable: Optionable
• Beta: 0.64